Opti-mAb™
improved scFv offering a new platform for biologics, bispecific antibodies and cell therapies
The antibody format field is moving rapidly forward with many new technologies being presented. Opti-mAb improves the stability and production of so-called scFv antibodies. This class of antibodies is used in new, rapidly growing therapeutic areas such as CAR-T and bispecific antibodies. Instability is a major problem in these areas, and no one else offers a widely applicable solution to this problem.
What is are single chain variable fragments (scFv)?
Single chain variable fragments (scFv) is an antibody format that was developed 30 years ago and is used for novel antibody-based therapeutics including bispecific antibodies and CAR-T cells.
While scFv antibodies offer numerous advantages, they are often plagued by inherent instability issues. This instability leads to high development costs and poor therapeutic performance, limiting their broad application. Both manufacturing and therapeutic use are affected by these drawbacks. The well-known stability problem of scFv has led to promising projects being canceled and is also one of the key problems in the CAR-T area.
What is Opti-mAb™?
With no other alternative provider for stabilizing scFv:s on the market, AAX Biotech provides Opti-mAb™, a unique and effective solution to overcome these challenges. Our approach involves a generally applicable molecular stabilization strategy that delivers multiple benefits.
Not only does Opti-mAb™ significantly improve production levels and enhance stability, but it also speeds up the development of new therapies for cancer and autoimmune diseases. This makes our solution a game-changer in the field of antibody therapeutics. CAR-T and bispecific antibodies have revolutionized both cancer treatment and autoimmune disease.
The Problem:
scFv antibodies have many advantages, but suffer from an inherent instability
Our Solution “Opti-mAb™”:
A generally applicable molecular stabilization strategy
Opti-mAb™: Increased yields and reduced aggregation
Increased yields
Elimination of aggregation
Why is it important?
Solving the scFv problem will expedite the development of new drugs, make these therapies more cost-effective as well as improve their therapeutic properties. This could also potentially revolutionize the antibody-based diagnostics market, such as lateral flow tests (pregnancy tests, covid tests etc.).